Enrofloxacin suspension and its prepn process

A technology of enrofloxacin and suspension, applied in the directions of liquid delivery, pharmaceutical formulation, emulsion delivery, etc., can solve the problems of short duration of drug effect, many injection times, large injection dose, etc. Simple production process and the effect of promoting absorption

Inactive Publication Date: 2005-12-14
史同瑞
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the dosage forms of enrofloxacin preparations are mainly powder and injection preparations, but the injections are all conventional water preparations, and the content is relatively low. The drug concentration is mostly 0.25%, 0.5% and 2.5%. Due to the low drug concentration, the drug effect lasts The time is short, so there are disadvantages such as large injection dose and many injection times

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1: prepare 10% enrofloxacin suspension

[0024] (1) Enrofloxacin 10g, n-butyl oleate 5g, polysorbate 5g, propylene glycol 40g and appropriate amount of distilled water are sterilized and stored for later use;

[0025] (2) Get polysorbate in mixing tank, add n-butyl oleate then, both are stirred;

[0026] (3) propylene glycol is added in the solution of step (2), mix;

[0027] (4) slowly add distilled water to 100g in the solution of step (3), and add antioxidant 0.5g, preservative 0.0005g, stir constantly, make emulsion base;

[0028] (5) Add the enrofloxacin to the matrix in step (4), stir evenly, fill and seal.

Embodiment 2

[0029] Embodiment 2: prepare 12% enrofloxacin suspension

[0030] (1) Enrofloxacin 12g, n-butyl oleate 3g, polysorbate 8g, propylene glycol 40g and appropriate amount of distilled water are sterilized and stored for later use;

[0031] (2) Get polysorbate in mixing tank, add n-butyl oleate then, both are stirred;

[0032] (3) propylene glycol is added in the solution of step (2), mix;

[0033] (4) slowly add distilled water to 100g in the solution of step (3), and add antioxidant 0.5g, preservative 0.0005g, stir constantly, make emulsion base;

[0034] (5) Add the enrofloxacin to the matrix in step (4), stir evenly, fill and seal.

Embodiment 3

[0035] Embodiment 3: prepare 8% enrofloxacin suspension

[0036] (1) Enrofloxacin 8g, n-butyl oleate 8g, polysorbate 3g, propylene glycol 50g and appropriate amount of distilled water are sterilized and stored for later use;

[0037] (2) Get polysorbate in mixing tank, add n-butyl oleate then, both are stirred;

[0038] (3) propylene glycol is added in the solution of step (2), mix;

[0039] (4) slowly add distilled water to 100g in the solution of step (3), and add antioxidant 0.5g, preservative 0.0005g, stir constantly, make emulsion base;

[0040] (5) Add the enrofloxacin to the matrix in step (4), stir evenly, fill and seal.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
flow consistencyaaaaaaaaaa
recovery rateaaaaaaaaaa
Login to view more

Abstract

The present invention is enroloxacin suspension and its preparation process and belongs to veterinary medicine technology. The enroloxacin suspension includes enroloxacin 8-12 wt%, butyl oleate 3-8 wt%, polysorbate 3-8 wt% and propylene glycol 30-50 wt% except water. The enroloxacin suspension is prepared through D phase emulsifying process, and is white and ropy. The enroloxacin suspension has slow release of the effective medicine component, high bioavailability, enhanced medicinal effect, long effective blood medicine concentration maintaining period up to 48 hr, low cost and other advantages.

Description

technical field [0001] The invention belongs to the technical field of animal husbandry pharmaceutical preparations, in particular to a suspension and a preparation method thereof. Background technique [0002] Enrofloxacin is a broad-spectrum quinolone antibacterial drug with broad antibacterial spectrum and strong antibacterial effect. Since the metabolite ciprofloxacin of enrofloxacin still has antibacterial effect, it is an ideal drug for the treatment of bacterial infections . Studies have confirmed that when enrofloxacin is used to treat endometritis in dairy cows by intrauterine infusion, enrofloxacin and its metabolite ciprofloxacin are rapidly eliminated in milk, and after 12 hours of administration, no residue can be detected by HPLC. Therefore, enrofloxacin will not form residues in milk. Therefore, the application of enrofloxacin in the treatment of livestock and poultry diseases such as dairy cows has positive significance for the production of non-antibiotic m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496
Inventor 史同瑞
Owner 史同瑞
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap